Skip to content

US · VOR · BIOTECHNOLOGY

Vor Biopharma Inc. (VOR) intrinsic value and stock valuation

$19.19as of 2026-11-21 · Mkt cap 1.21B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vor Biopharma Inc. DCF and intrinsic value

InvestorsCraft values VOR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VOR’s statements →

Vor Biopharma Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02116 vorbio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-695.98M
20182025
Free cash flow
-$-143.65M
20182025
Total equity
-$-164.31M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-371.64M-$-121.19M-$-126.04M-$-93.42M-$-69.02M
Net income-$-695.98M-$-116.91M-$-117.86M-$-92.09M-$-68.9M
EPSd-$-70.51M-$-33.99M-$-35.08M-$-46.51M-$-37.04M
Operating cash flow-$-142.71M-$-99.66M-$-100.29M-$-85.14M-$-69.14M
Capital expenditure-$-940K-$-230K-$-1.07M-$-8.46M-$-3.89M
Free cash flow-$-143.65M-$-99.89M-$-101.36M-$-93.61M-$-73.04M
Total assets$464.1M$142.9M$209.8M$299.4M$242.6M
Total debt$3M$31.8M$35.7M$38.9M$18M
Net debt-$-393.49M-$-50.12M$4.3M-$-18.79M-$-101.79M
Total equity-$-164.31M$96.7M$150.7M$250.6M$216.3M
Cash and short-term investments$455.2M$91.9M$137.2M$230.3M$207.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$3.49M$8.96M$0.00
Gross profit$0.00$0.00-$-3.49M-$-8.96M$0.00
Research and development expenses$321.5M$93.3M$94.3M$64.6M$47.5M
Selling, general and administrative expenses$50.1M$27.9M$31.7M$19.9M$21.5M
Other expenses$0.00$0.00-$-3.49M$0.00$0.00
Operating expenses$371.6M$121.2M$122.5M$84.5M$69M
Cost and expenses$371.6M$121.2M$126M$93.4M$69M
Interest income$5.87M$4.27M$8.17M$1.32M$120K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.89M$3.53M$3.49M$8.96M$1.43M
Ebitda-$-693.09M-$-113.39M-$-114.37M-$-83.13M-$-67.47M
Operating income-$-371.64M-$-121.19M-$-126.04M-$-93.42M-$-69.02M
Total other income/expenses, net-$-324.34M$4.27M$8.17M$1.32M$120K
Income before tax-$-695.98M-$-116.91M-$-117.86M-$-92.09M-$-68.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-695.98M-$-116.91M-$-117.86M-$-92.09M-$-68.9M
Weighted average shares outstanding$9.87M$3.44M$3.36M$1.98M$1.86M
Weighted average diluted shares outstanding$9.87M$3.44M$3.36M$1.98M$1.86M
Balance sheet
20252024202320222021
Cash and short-term investments$455.2M$91.9M$137.2M$230.3M$207.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$458.1M$96.5M$140.8M$237M$214.4M
Property, plant and equipment, net$3.47M$41.6M$50.1M$57.1M$22.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$2.41M$2.41M$0.00
Total non-current assets$6.02M$46.4M$69M$62.4M$28.2M
Total assets$464.1M$142.9M$209.8M$299.4M$242.6M
Accounts payable$5.13M$1.5M$810K$1.77M$1.54M
Short-term debt$280K$4.21M$3.83M$3.27M$1.84M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$25.2M$18.6M$15.6M$13.1M$10.2M
Long-term debt$2.72M$27.6M$31.8M$35.6M$16.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$603.3M$27.6M$43.5M$35.6M$16.2M
Capital lease obligations$2.72M$31.8M$31.8M$38.9M$18M
Total liabilities$628.4M$46.2M$59.1M$48.8M$26.3M
Common stock$20K$10K$10K$10K$0.00
Retained earnings-$-1.15B-$-456.99M-$-340.08M-$-222.22M-$-130.12M
Accumulated other comprehensive income (loss)$40K$20K-$-80K-$-770K$0.00
Total equity-$-164.31M$96.7M$150.7M$250.6M$216.3M
Total investments$58.7M$9.98M$108.2M$175M$87.7M
Total debt$3M$31.8M$35.7M$38.9M$18M
Net debt-$-393.49M-$-50.12M$4.3M-$-18.79M-$-101.79M
Cash flow statement
20252024202320222021
Net income-$-695.98M-$-116.91M-$-117.86M-$-92.09M-$-68.9M
Depreciation and amortization$2.89M$3.53M$3.49M$2.52M$1.43M
Stock-based compensation$18.9M$9.85M$13.4M$10.7M$4.32M
Change in working capital$10.2M$10K$650K-$-12.69M-$-9.19M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$2.24M$2.85M$0.00$410K
Net cash provided by operating activities-$-142.71M-$-99.66M-$-100.29M-$-85.14M-$-69.14M
Investments in property, plant and equipment-$-940K-$-230K-$-1.07M-$-8.46M-$-3.89M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-48.8M$96.9M$71M-$-94.09M-$-91.65M
Common stock issued$505.1M$55.8M$4.58M$116M$189.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$503.8M$53.4M$2.94M$117.1M$232.9M
Net change in cash$312.3M$50.6M-$-26.35M-$-62.09M$72.1M
Cash at end of period$396.7M$84.4M$33.8M$60.1M$122.2M
Operating cash flow-$-142.71M-$-99.66M-$-100.29M-$-85.14M-$-69.14M
Capital expenditure-$-940K-$-230K-$-1.07M-$-8.46M-$-3.89M
Free cash flow-$-143.65M-$-99.89M-$-101.36M-$-93.61M-$-73.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vor Biopharma Inc.

        Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

        CEO
        Jean-Paul Kress
        Employees
        76
        Beta
        1.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Vor Biopharma Inc. (VOR)?

        InvestorsCraft does not currently publish an intrinsic value for VOR. How the IC value is calculated.

        Is VOR undervalued?

        InvestorsCraft does not publish an undervaluation signal for VOR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.